SRPT Sarepta Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-14
$17.96 -4.6%
$1.90B mkt cap
executive summary
Sarepta Therapeutics, Inc. (SRPT) is a $1.90B company. Revenue is $2.18B (-2.2% y/y) at a 3% net margin. It is profitable. Our health score is D (43/100). 2 red flags on file. It funds itself; low dilution risk.
Revenue (TTM)
$2.18B
-2.2% y/y
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-1.14).
⚠Weak fundamentals
Piotroski F-Score of 2/9 — most quality checks are failing.
who's buying
Insider buys / sells
0 / 1
Cash & ST investments
$653.2M
Operating cash flow
-$205.5M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-14 by stocktools.ai.